Seminars in arthritis and rheumatism · 2026
Cancer-associated myositis in Chinese patients with idiopathic inflammatory myopathies: Malignancy spectrum, risk factors, and validation of the IMACS guideline.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Can, Wang Runci, Lyu Xia, Ye Yan, Wu Wanlong, Fu Yakai, Cao Hua, Gao Yingying, Huang Jiao, Yi Jiang, Chen He, Wang Meiying, Ye Shuang, Fu Qiong
Аннотация
OBJECTIVE: To characterize malignancy patterns in Chinese patients with idiopathic inflammatory myopathies (IIM) and evaluate the real-world applicability of the International Myositis Assessment and Clinical Studies Group (IMACS) cancer screening guideline.
METHODS: This multi-centre retrospective study included adult patients with IIM from five tertiary referral centers in China between January 2010 and December 2024. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after IIM onset. Logistic regression analyses were performed to identify factors associated with malignancy, and a simplified refinement score was developed to assess its incremental value beyond the IMACS guideline.
RESULTS: Among 1980 eligible patients with IIM, 176 (8.9%) had CAM. Lung cancer (18.2%), breast cancer (14.8%), and thyroid cancer (11.9%) were the most common malignancies. Overall, 76.1% of cancers occurred within 1 year before or after IIM onset. According to the IMACS guideline, 65.9% of CAM patients were classified as high-risk, whereas 65.4% of non-CAM patients were also assigned to the moderate-risk category. Multivariable analysis identified anti-TIF1γ antibody positivity, anti-SAE antibody positivity, elevated C-reactive protein, and elevated CA125 as independent risk factors, whereas interstitial lung disease was inversely associated with malignancy. A refinement score incorporating anti-SAE antibody positivity, elevated C-reactive protein, elevated CA125, and absence of interstitial lung disease further stratified malignancy risk within IMACS categories and improved discrimination compared with IMACS alone (AUC 0.762 vs. 0.699, P < 0.001).
CONCLUSION: The IMACS guideline effectively identifies patients at increased malignancy risk, and a simple refinement score may further improve risk stratification.
METHODS: This multi-centre retrospective study included adult patients with IIM from five tertiary referral centers in China between January 2010 and December 2024. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after IIM onset. Logistic regression analyses were performed to identify factors associated with malignancy, and a simplified refinement score was developed to assess its incremental value beyond the IMACS guideline.
RESULTS: Among 1980 eligible patients with IIM, 176 (8.9%) had CAM. Lung cancer (18.2%), breast cancer (14.8%), and thyroid cancer (11.9%) were the most common malignancies. Overall, 76.1% of cancers occurred within 1 year before or after IIM onset. According to the IMACS guideline, 65.9% of CAM patients were classified as high-risk, whereas 65.4% of non-CAM patients were also assigned to the moderate-risk category. Multivariable analysis identified anti-TIF1γ antibody positivity, anti-SAE antibody positivity, elevated C-reactive protein, and elevated CA125 as independent risk factors, whereas interstitial lung disease was inversely associated with malignancy. A refinement score incorporating anti-SAE antibody positivity, elevated C-reactive protein, elevated CA125, and absence of interstitial lung disease further stratified malignancy risk within IMACS categories and improved discrimination compared with IMACS alone (AUC 0.762 vs. 0.699, P < 0.001).
CONCLUSION: The IMACS guideline effectively identifies patients at increased malignancy risk, and a simple refinement score may further improve risk stratification.